name: Ambulatory blood pressure monitoring, utilizing report-generating software, automated, worn continuously for 24 hours or longer; review with interpretation and report


name: Review of ambulatory blood pressure monitoring for 24 hours or longer, with interpretation and report


name: Duplex scan of arterial inflow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access


name: Duplex scan of arterial inflow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access; complete bilateral study


name: Duplex scan of arterial inflow and venous outflow for preoperative vessel assessment prior to creation of hemodialysis access; complete unilateral study


name: Electroencephalogram (EEG) continuous recording, with video when performed, setup, patient education, and takedown when performed, administered in person by EEG technologist, minimum of 8 channels


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours; unmonitored


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours; with intermittent monitoring and maintenance


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, 2-12 hours; with continuous, real-time monitoring and maintenance


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours; unmonitored


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours; with intermittent monitoring and maintenance


name: Electroencephalogram (EEG), without video, review of data, technical description by EEG technologist, each increment of 12-26 hours; with continuous, real-time monitoring and maintenance


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours; unmonitored


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours; with intermittent monitoring and maintenance


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, 2-12 hours; with continuous, real-time monitoring and maintenance


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours; unmonitored


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours; with intermittent monitoring and maintenance


name: Electroencephalogram with video (VEEG), review of data, technical description by EEG technologist, each increment of 12-26 hours; with continuous, real-time monitoring and maintenance


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording; without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation and report, 2-12 hours of EEG recording; with video (VEEG)


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, each increment of greater than 12 hours, up to 26 hours of EEG recording, interpretation and report after each 24-hour period; with video (VEEG)


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 36 hours, up to 60 hours of EEG recording, without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 36 hours, up to 60 hours of EEG recording, with video (VEEG)


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 60 hours, up to 84 hours of EEG recording, without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 60 hours, up to 84 hours of EEG recording, with video (VEEG)


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 84 hours of EEG recording, without video


name: Electroencephalogram (EEG), continuous recording, physician or other qualified health care professional review of recorded events, analysis of spike and seizure detection, interpretation, and summary report, complete study; greater than 84 hours of EEG recording, with video (VEEG)


name: Health behavior assessment, or re-assessment (ie, health-focused clinical interview, behavioral observations, clinical decision making)


name: Health behavior intervention, individual, face-to-face


name: Health behavior intervention, individual, face-to-face; initial 30 minutes


name: Health behavior intervention, individual, face-to-face; each additional 15 minutes (List separately in addition to code for primary service)


name: Face-to-face individual health behavior intervention, each additional 15 minutes


name: Health behavior intervention, group (2 or more patients), face-to-face


name: Health behavior intervention, group (2 or more patients), face-to-face; initial 30 minutes


name: Face-to-face group health behavior intervention, initial 30 minutes


name: Health behavior intervention, group (2 or more patients), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)


name: Face-to-face group health behavior intervention, each additional 15 minutes


name: Health behavior intervention, family (with the patient present), face-to-face


name: Health behavior intervention, family (with the patient present), face-to-face; initial 30 minutes


name: Health behavior intervention, family (with the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)


name: Face-to-face family (with patient present) health behavior intervention, each additional 15 minutes


name: Health behavior intervention, family (without the patient present), face-to-face


name: Health behavior intervention, family (without the patient present), face-to-face; initial 30 minutes


name: Health behavior intervention, family (without the patient present), face-to-face; each additional 15 minutes (List separately in addition to code for primary service)


name: Face-to-face family (without patient present) health behavior intervention, each additional 15 minutes


name: Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact


name: Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; initial 15 minutes


name: Therapeutic interventions that focus on cognitive function and compensatory strategies to manage the performance of an activity, direct (one-on-one) patient contact, initial 15 minutes


name: Therapeutic interventions that focus on cognitive function (eg, attention, memory, reasoning, executive function, problem solving, and/or pragmatic functioning) and compensatory strategies to manage the performance of an activity (eg, managing time or schedules, initiating, organizing, and sequencing tasks), direct (one-on-one) patient contact; each additional 15 minutes (List separately in addition to code for primary procedure)


name: Therapeutic interventions that focus on cognitive function and compensatory strategies to manage the performance of an activity, direct (one-on-one) patient contact, each additional 15 minutes


name: Nonphysician qualified health care professional online digital assessment and management, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes


name: Self-measured blood pressure using a device validated for clinical accuracy


name: Self-measured blood pressure using a device validated for clinical accuracy; patient education/training and device calibration


name: Self-measured blood pressure using a device validated for clinical accuracy; separate self-measurements of two readings one minute apart, twice daily over a 30-day period (minimum of 12 readings), collection of data reported by the patient and/or caregiver to the physician or other qualified health care professional, with report of average systolic and diastolic pressures and subsequent communication of a treatment plan to the patient


name: Self measured blood pressure measurements


name: Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days


name: Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 5-10 minutes


name: Online digital evaluation and management service, for established patient, for up to 7 days, cumulative time 5-10 minutes


name: Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 11-20 minutes


name: Online digital evaluation and management service, for an established patient, for up to 7 days, cumulative time during the 7 days; 21 or more minutes


name: Online digital evaluation and management service, for established patient, for up to 7 days, cumulative time 21 or more minutes


name: Remote physiologic monitoring treatment management services, clinical staff/physician/other qualified health care professional time in a calendar month requiring 1 real-time interactive communication with the patient/caregiver during the calendar month; each additional 20 minutes (List separately in addition to code for primary procedure)


name: Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed


name: Dilated retinal eye exam with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of retinopathy (DM)


name: 7 standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed


name: 7 standard field stereoscopic retinal photos with interpretation by an ophthalmologist or optometrist documented and reviewed; without evidence of retinopathy (DM)


name: Eye imaging validated to match diagnosis from 7 standard field stereoscopic retinal photos results documented and reviewed


name: Eye imaging validated to match diagnosis from 7 standard field stereoscopic retinal photos results documented and reviewed; without evidence of retinopathy (DM)


name: Most recent hemoglobin A1c (HbA1c) level greater than or equal to 7.0% and less than 8.0% (DM)


name: Most recent hemoglobin A1c (HbA1c) level greater than or equal to 8.0% and less than or equal to 9.0% (DM)


name: Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae


name: Repair of valve between upper left and lower left chambers of heart (mitral valve) with insertion of artificial supporting tendons, accessed through apex of heart


name: Transcatheter mitral valve annulus reconstruction, with implantation of adjustable annulus reconstruction device, percutaneous approach including transseptal puncture


name: Reconstruction of junction between upper left and lower left chambers of heart (annulus of mitral valve) with implantation of adjustable reconstruction device, via catheter, accessed through skin


name: Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach


name: Reconstruction of junction between upper right and lower right chambers of heart (annulus of tricuspid valve) with implantation of adjustable reconstruction device, via catheter, accessed through skin


name: Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report


name: Radiofrequency spectroscopy evaluation of surgical margins during partial mastectomy, with report


name: Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score


name: Bone material quality testing by microindentations of shin bone


name: Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance


name: Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance


name: Periurethral transperineal adjustable balloon continence device; removal, each balloon


name: Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume


name: Low-level laser therapy, dynamic photonic and dynamic thermokinetic energies, provided by a physician or other qualified health care professional


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone-mineral density, interpretation and report


name: Bone strength and fracture risk assessment: retrieval and transmission of CT scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; retrieval and transmission of the scan data


name: Bone strength and fracture risk assessment: retrieval and transmission of CT scan data only


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone-mineral density


name: Bone strength and fracture risk assessment: assessment of bone strength and fracture risk and bone mineral density


name: Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density utilizing data from a computed tomography scan; interpretation and report


name: Bone strength and fracture risk assessment: interpretation and report


name: Computed tomography scan taken for the purpose of biomechanical computed tomography analysis


name: CT scan for biomechanical computed tomography analysis


name: Anatomic model 3D-printed from image data set(s)


name: Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure


name: 3-D printed anatomic model; first individually prepared and processed component of anatomic structure


name: Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)


name: 3-D printed anatomic model; each additional individually prepared and processed component of anatomic structure


name: Anatomic guide 3D-printed and designed from image data set(s)


name: Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide


name: Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure)


name: 3-D printed anatomic guide; each additional guide


name: Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral


name: Evacuation of meibomian tear glands of eyelids of both eyes


name: Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees


name: Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation


name: Harvesting of fatty tissue and creation of cellular implant for treatment of osteoarthritis


name: Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral


name: Injection of fatty tissue cellular implant for treatment of osteoarthritis in knee, using ultrasound guidance


name: transcatheter tricuspid valve repair, percutaneous approach


name: Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis


name: Repair of valve between upper right and lower right chambers of heart (tricuspid valve) using prosthesis delivered via catheter, accessed through skin; initial prosthesis


name: Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)


name: Repair of valve between upper right and lower right chambers of heart (tricuspid valve) using prosthesis delivered via catheter, accessed through skin; each additional prosthesis


name: Insertion or replacement of implantable cardioverter-defibrillator system with substernal electrode(s), including all imaging guidance and electrophysiological evaluation (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters), when performed


name: Insertion or replacement of implantable cardioverter-defibrillator system with electrodes under breastbone


name: Insertion of substernal implantable defibrillator electrode


name: Insertion of implantable defibrillator electrode under breastbone


name: Removal of substernal implantable defibrillator electrode


name: Removal of implantable defibrillator electrode from under breastbone


name: Repositioning of previously implanted substernal implantable defibrillator-pacing electrode


name: Repositioning of previously implanted defibrillator electrode under breastbone


name: Programming device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional


name: In-person programming device evaluation of implantable cardioverter-defibrillator system with electrode under breastbone, with analysis, review and report


name: Interrogation device evaluation (in person) of implantable cardioverter-defibrillator system with substernal electrode, with analysis, review and report by a physician or other qualified health care professional, includes connection, recording and disconnection per patient encounter


name: In-person interrogation device evaluation of implantable cardioverter-defibrillator system with electrode under breastbone, with analysis, review and report


name: Electrophysiologic evaluation of implantable cardioverter-defibrillator system with substernal electrode (includes defibrillation threshold evaluation, induction of arrhythmia, evaluation of sensing for arrhythmia termination, and programming or reprogramming of sensing or therapeutic parameters)


name: Electrophysiological evaluation of implantable cardioverter-defibrillator system with electrode under breastbone, with analysis, review and report


name: Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system with interim analysis, review(s) and report(s) by a physician or other qualified health care professional


name: Remote interrogation device evaluation of implantable cardioverter-defibrillator system with lead under breastbone, with analysis, review and report by healthcare professional


name: Interrogation device evaluation(s) (remote), up to 90 days, substernal lead implantable cardioverter-defibrillator system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results


name: Remote interrogation device evaluation of implantable cardioverter-defibrillator system with lead under breastbone, with remote data acquisitions, receipt of transmissions and technician review, technical support and distribution of results


name: Removal of substernal implantable defibrillator pulse generator only


name: Removal of implantable defibrillator pulse generator from under breastbone


name: Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral


name: Freezing destruction of malignant breast tumors in one breast, accessed through skin


name: Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance


name: High-energy water vapor heat destruction of malignant prostate tissue, including imaging and needle guidance


name: Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia


name: Insertion of ventilating tube in eardrum using an automated tube delivery system under local anesthesia


name: Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed


name: Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; percutaneous


name: Transplantation of insulin-producing cells, via catheter accessed through skin using imaging guidance


name: Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; laparoscopic


name: Transplantation of insulin-producing cells using endoscope inserted through wall of abdomen


name: Islet cell transplant, includes portal vein catheterization and infusion, including all imaging, including guidance, and radiological supervision and interpretation, when performed; open


name: Transplantation of insulin-producing cells, open procedure


name: Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve


name: Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve


name: Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters


name: Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters


name: face-to-face health and well-being coaching


name: Health and well-being coaching face-to-face; individual, initial assessment


name: Health and well-being coaching face-to-face; individual, follow-up session, at least 30 minutes


name: Health and well-being coaching face-to-face; group (2 or more individuals), at least 30 minutes


name: Face-to-face health and well-being coaching of group, at least 30 minutes


name: Multianalyte Assays with Algorithmic Analyses and Proprietary Laboratory Analyses


name: Immobilized Metal Affinity Chromatography


name: Clinical Regional Lymph Nodes TNM Finding


name: Stable Isotope Labeling with Amino Acids in Cell Culture


name: Chemokine (C-C Motif) Ligand 20 Measurement


name: MLH1 Gene Promoter Hypermethylation Negative


name: International Prognostic Index Low Risk Group


name: Montreal Cognitive Assessment Naming Test


name: Supraventricular Bigeminy by ECG Finding


name: Chemokine (C-X-C Motif) Ligand 11 Measurement


name: Montreal Cognitive Assessment Total Score


name: Unspecified Cells to Leukocytes Ratio Measurement


name: Montreal Cognitive Assessment Orientation Test


name: CDISC SDTM Implementation Guide Version 3.2


name: CDISC SDTM Implementation Guide Version 3.3


name: Urinary System Findings Completion Status


name: Global Progressive Disease in Lymph Nodes


name: Human Immunodeficiency Virus Measurement


name: International Prognostic Index High Risk Group


name: Caregiver Oncology Needs Evaluation Tool


name: Chemokine (C-X3-C Motif) Ligand 1 Measurement


name: Erythrocyte Inclusion Bodies Measurement


name: Stereotactic Accelerated Partial Breast Irradiation


name: Montreal Cognitive Assessment Abstraction Test


name: Adjacent Tissue Transfer or Rearrangement


name: Mental health screening report:Find:Pt:^Patient:Doc


name: Guidance for percutaneous biopsy of Liver


name: laceration of right eye (physical finding)


name: PhenX - complete blood count protocol 220501:-:Pt:^Patient:-:PhenX


name: PhenX - complete blood count protocol 220501


name: {1 (0.1 ML) (diazepam 100 MG/ML Nasal Spray [Valtoco]) } Pack [Valtoco 10 MG Dose Kit]


name: {2 (0.1 ML) (diazepam 100 MG/ML Nasal Spray [Valtoco]) } Pack [Valtoco 20 MG Dose Kit]


name: Somatic symptom disorder score:Score:Pt:^Patient:Qn


name: Somatic symptom disorder screening report:Find:Pt:^Patient:Doc


name: Somatic symptom disorder screening report


name: Appointment of legal guardian:Find:Pt:^Patient:Nom


name: ADHD question consistency score:Score:Pt:^Patient:Qn


name: Megalencephaly Cutis Marmorata Telangiectatica Congenita (test kit)


name: Measured weight loss (observable entity)


name: Growth hormone receptor antagonist (disposition)


name: Accessibility of home entrance:Find:Pt:^Patient:Nom


name: Accessibility of home interior:Find:Pt:^Patient:Nom


name: Non-specific active suicidal thoughts:Find:Lifetime:^Patient:Ord


name: WellRx Questionnaire - revised:-:Pt:^Patient:-:WellRx


name: CD19 blasts/100 blasts in blood (lab test)


name: CT Guidance for injection of Joint space


name: CT Guidance for drainage and placement of drainage catheter of appendix


name: MR Guidance for stereotactic biopsy of Brain


name: Patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2127)


name: Substance with acetylcholinesterase reactivator mechanism of action (substance)


name: Product containing vasopressin receptor agonist (product)


name: Vasopressin receptor agonist (disposition)


name: Product containing smoothened receptor agonist (product)


name: Smoothened receptor agonist (disposition)


name: Substance with sodium-hydrogen exchanger isoform 3 transporter inhibitor mechanism of action (substance)


name: Guidance for kyphoplasty of Lumbar spine


name: ADHD hyperactive symptoms severity:Imp:Pt:^Patient:Ord


name: ADHD inattentive symptoms severity:Imp:Pt:^Patient:Ord


name: Advance directive document format:Find:Pt:^Patient:Nom


name: Wish to be dead:Find:Lifetime:^Patient:Ord


name: CT Guidance for drainage and placement of drainage catheter of pancreas


name: CD127 blasts/100 blasts in blood (lab test)


name: Drug classes of medications taken:Type:RptPeriod:^Patient:Nom:CMS Assessment


name: Genetic risk score for coronary heart disease


name: Genetic risk score for coronary heart disease:Score:Lifetime:^Patient:Qn


name: Home accessibility modification date:Date:Pt:^Patient:Qn


name: CT Guidance for drainage and placement of drainage catheter of subphrenic space


name: Dermatan sulfate & heparan sulfate & keratan sulfate panel


name: Dermatan sulfate & heparan sulfate & keratan sulfate panel:-:Pt:Ser/Plas:-


name: little c Ag^during infancy:PrThr:Pt:RBC:Ord


name: HEDIS 2020 Value Set - Mammography:-:Pt:^Patient:-


name: Total parenteral nutrition agent (substance)


name: Bone age assessment - Tanner-Whitehouse (TW2) associated observations panel:-:Pt:^Patient:-


name: Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery for surgery or hospitalized (M1140)


name: Comparison with previous results:Find:Pt:^Patient:Doc


name: PhenX - bone age protocol 220301:-:Pt:^Patient:-:PhenX


name: Body disposition facility name:ID:Pt:Facility:Nom


name: CD11c+CD19+ cells/100 cells in bone marrow


name: cytoplasmic CD22 blasts/100 blasts in blood


name: cytoplasmic CD13 blasts/100 blasts in blood


name: Sodium-hydrogen exchanger isoform 3 transporter inhibitor (disposition)


name: {28 (tolvaptan 15 MG Oral Tablet [Jynarque]) / 28 (tolvaptan 30 MG Oral Tablet [Jynarque]) } Pack [Jynarque 30/15 Carton]


name: {56 (tolvaptan 15 MG Oral Tablet [Jynarque]) } Pack [Jynarque 15/15 Carton]


name: CD11c+CD19+ cells/100 cells in cerebral spinal fluid


name: E Ag^post hematopoietic stem cell transplant:PrThr:Pt:RBC:Ord


name: little e Ag^post hematopoietic stem cell transplant:PrThr:Pt:RBC:Ord


name: Substance use disorder screening report:Find:Pt:^Patient:Doc


name: Cause of sick feeling:Find:Pt:^Patient:Nom


name: CD11c+CD19+ cells/100 cells in body fluid


name: CD11c+CD19+ cells/100 cells in tissue (lab test)


name: CD123 blasts/100 blasts in blood (lab test)


name: Best thing about your day:Find:Pt:^Patient:Nom


name: Body disposition facility address:Addr:Pt:Facility:Nom


name: Bone age assessment - Tanner-Whitehouse (TW2) associated observations panel


name: Date and time of obstetric delivery:TmStp:Pt:^Patient:Qn


name: Date of most lethal suicide attempt:Date:Pt:^Patient:Qn


name: Date of most recent suicide attempt:Date:Pt:^Patient:Qn


name: CD14 blasts/100 blasts in blood (lab test)


name: CD16 blasts/100 blasts in blood (lab test)


name: CD1a blasts/100 blasts in blood (lab test)


name: Central alpha-2 adrenergic receptor agonist (disposition)


name: Substance with central alpha-2 adrenergic receptor agonist mechanism of action (substance)


name: little c Ag^post hematopoietic stem cell transplant:PrThr:Pt:RBC:Ord


name: C Ag^post hematopoietic stem cell transplant:PrThr:Pt:RBC:Ord


name: C Ag^post transfusion reaction:PrThr:Pt:RBC:Ord


name: little c Ag^post transfusion reaction:PrThr:Pt:RBC:Ord


name: DPYD gene targeted mutation analysis:Find:Pt:Bld/Tiss:Doc:Molgen


name: little e Ag^during infancy:PrThr:Pt:RBC:Ord


name: E Ag^post transfusion reaction:PrThr:Pt:RBC:Ord


name: little e Ag^post transfusion reaction:PrThr:Pt:RBC:Ord


name: CT Guidance for drainage and placement of drainage catheter of abdomen


name: CT Guidance for drainage and placement of drainage catheter of anus


name: CT Guidance for drainage and placement of drainage catheter of biliary ducts and gallbladder


name: CT Guidance for drainage and placement of drainage catheter of chest


name: CT Guidance for drainage and placement of drainage catheter of gallbladder


name: CT Guidance for drainage and placement of drainage catheter of kidney


name: CT Guidance for drainage and placement of drainage catheter of liver


name: CT Guidance for drainage and placement of drainage catheter of pelvis


name: CT Guidance for drainage and placement of drainage catheter of retroperitoneum


name: CT Guidance for exchange of nephrostomy tube of Kidney


name: CT guidance for fluid aspiration of breast


name: CT guidance for fluid aspiration of cervical spine intervertebral disc


name: CT guidance for fluid aspiration of chest


name: CT guidance for fluid aspiration of liver


name: CT guidance for fluid aspiration of lung


name: CT guidance for fluid aspiration of neck


name: CT guidance for fluid aspiration of pancreas


name: CT guidance for fluid aspiration of pleural space


name: CT Guidance for injection of Cervical spine Intervertebral disc


name: CT Guidance for localization of placenta of Uterus


name: CT guidance for needle localization of breast


name: CT guidance for needle localization of cervical spine


name: CT Guidance for needle localization of Lumbar spine


name: CT Guidance for needle localization of Thoracic spine


name: CT Guidance for percutaneous replacement of drainage tube of Abdomen


name: CT Guidance for percutaneous replacement of drainage tube of Pelvis


name: CT Guidance for percutaneous vertebroplasty of Lumbar spine


name: CT Guidance for percutaneous vertebroplasty of Thoracic spine


name: CT Guidance for placement of nephrostomy tube in Kidney


name: cytoplasmic CD179a blasts/100 blasts in blood


name: Guidance for drainage and placement of chest tube of Pleural space


name: Guidance for injection of Spine epidural space


name: Guidance for injection of Temporomandibular joint


name: Guidance for kyphoplasty of Thoracic spine


name: Guidance for percutaneous biopsy of Kidney


name: HEDIS 2020 Value Set - Urine Protein Tests


name: HEDIS 2020 Value Set - Urine Protein Tests:-:Pt:^Patient:-


name: tissue injury of both ankles (physical finding)


name: Home accessibility evaluation status:Find:Pt:^Patient:Nom


name: Home accessibility modification panel:-:Pt:^Patient:-


name: Home accessibility modification responsible party:Find:Pt:^Patient:Nom


name: Home accessibility modification responsible party


name: HEDIS 2020 Value Set - BMI:-:Pt:^Patient:-


name: HEDIS 2020 Value Set - BMI percentile:-:Pt:^Patient:-


name: HEDIS 2020 Value Set - CT Colonography:-:Pt:^Patient:-


name: HEDIS 2020 Value Set - Diastolic Blood Pressure:-:Pt:^Patient:-


name: HEDIS 2020 Value Set - Diastolic Blood Pressure


name: HEDIS 2020 Value Set - Systolic Blood Pressure:-:Pt:^Patient:-


name: HEDIS 2020 Value Set - Systolic Blood Pressure


name: Setting of exposure to environmental or occupational hazard:Type:Pt:^Patient:Nom


name: Setting of exposure to environmental or occupational hazard


name: Lifetime risk for developing coronary heart disease based on genetic risk score:Likelihood:Lifetime:^Patient:Ord


name: Lifetime risk for developing coronary heart disease based on genetic risk score


name: Somatic symptom disorder severity:Imp:Pt:^Patient:Ord


name: Substance use disorder question consistency score


name: Substance use disorder question consistency score:Score:Pt:^Patient:Qn


name: Substance use disorder score:Score:Pt:^Patient:Qn


name: Medical records in response to authorization denial


name: Medical records in response to authorization denial:Find:Pt:^Patient:Doc


name: Substance use disorder severity:Imp:Pt:^Patient:Ord


name: Insertion of composite restoration using strip crown


name: Healthy Eating Index 2015 score (observable entity)


name: Healthy Eating Index 2015 (assessment scale)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2109)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2098)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2106)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2100)


name: Patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2115)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2090)


name: Patients age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 days during the measurement period (G2130)


name: Patients age 66 and older in institutional special needs plans (snp) or residing in long-term care with a pos code 32, 33, 34, 54 or 56 for more than 90 days during the measurement period (G9910)


name: Patient age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period (G2108)


name: Patient age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period (G2105)


name: Patients age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the six months prior to the measurement period through december 31 of the measurement period


name: Monocyte chemotactic protein-2 measurement


name: Discharge/discontinuation of the episode of care documented in the medical record (M1009)


name: Discharge/discontinuation of the episode of care documented in the medical record (M1012)


name: Discharge/discontinuation of the episode of care documented in the medical record (M1014)


name: Discharge/discontinuation of the episode of care documented in the medical record (M1011)


name: Discharge/discontinuation of the episode of care documented in the medical record (M1010)


name: Discharge/discontinuation of the episode of care documented in the medical record (M1013)


name: Discharge/discontinuation of the episode of care documented in the medical record (M1015)


name: Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care (M1112)


name: Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care (M1107)


name: Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care (M1122)


name: Ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record (M1118)


name: Ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record (M1108)


name: The start of an episode of care documented in the medical record (M1135)


name: The start of an episode of care documented in the medical record (M1111)


name: Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care (M1137)


name: Ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record (M1123)


name: Ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record (M1128)


name: Ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record (M1113)


name: Ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown) (M1130)


name: Ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown) (M1115)


name: Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care (M1117)


name: Functional status measured by the oxford knee score (oks) at one year (9 to 15 months) postoperatively was less than 37 or the knee injury and osteoarthritis outcome score joint replacement (koos, jr.) was less than 71 postoperatively


name: Functional status measured by the oxford knee score (oks) at one year (9 to 15 months) postoperatively was greater than or equal to 37 or knee injury and osteoarthritis outcome score joint replacement (koos, jr.) was greater than or equal to 71


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2107)


name: Patients 66 years of age or older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2135)


name: Patients 66 - 80 years of age with at least one claim/encounter for frailty during the measurement period and an advanced illness diagnosis during the measurement period or the year prior to the measurement period


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2110)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2101)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2099)


name: Patients 66 years of age and older with at least one claim/encounter for frailty during the measurement period and an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2091)


name: Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2133)


name: Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and either one acute inpatient encounter with a diagnosis of advanced illness or two outpatient, observation, ed or nonacute inpatient encounters on different dates of service with an advanced illness diagnosis during the measurement period or the year prior to the measurement period (G2117)


name: Patients 81 years and older with a diagnosis of frailty


name: Patients 81 years of age and older with at least one claim/encounter for frailty during the six months prior to the measurement period through december 31 of the measurement period


name: Patients 81 years of age and older with at least one claim/encounter for frailty during the measurement period


name: Patient age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54 or 56 for more than 90 consecutive days during the measurement period (G9901)


name: Patients age 66 or older in institutional special needs plans (snp) or residing in long-term care with pos code 32, 33, 34, 54, or 56 for more than 90 consecutive days during the measurement period (G9898)


name: Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2132)


name: Patients 66-80 years of age with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2114)


name: Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care (M1127)


name: Ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown) (M1120)


name: The start of an episode of care documented in the medical record (M1121)


name: Ongoing care not clinically indicated because the patient needed a home program only, referral to another provider or facility, or consultation only, as documented in the medical record (M1132)


name: Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown) (M1125)


name: Ongoing care not indicated, patient seen only 1-2 visits (e.g., home program only, referred to another provider or facility, consultation only) (M1138)


name: Ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery (M1114)


name: The start of an episode of care documented in the medical record (M1106)


name: The start of an episode of care documented in the medical record (M1136)


name: The start of an episode of care documented in the medical record (M1116)


name: Ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery (M1109)


name: Documentation stating patient has a diagnosis of a degenerative neurological condition such as als, ms, or parkinson's diagnosed at any time before or during the episode of care (M1131)


name: Ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery (M1133)


name: Ongoing care not indicated, patient discharged after only 1-2 visits due to specific medical events, documented in the medical record that make the treatment episode impossible such as the patient becomes hospitalized or scheduled for surgery (M1124)


name: The start of an episode of care documented in the medical record (M1126)


name: Ongoing care not indicated, patient self-discharged early and seen only 1-2 visits (e.g., financial or insurance reasons, transportation problems, or reason unknown)


name: Ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown) (M1148)


name: Ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery (M1119)


name: Ongoing care not medically possible because the patient was discharged early due to specific medical events, documented in the medical record, such as the patient became hospitalized or scheduled for surgery (M1129)


name: Ongoing care not possible because the patient self-discharged early (e.g., financial or insurance reasons, transportation problems, or reason unknown) (M1134)


name: Patients 66 years of age or older with at least one claim/encounter for frailty during the measurement period and a dispensed medication for dementia during the measurement period or the year prior to the measurement period (G2134)


name: Was Menopausal Hormone Therapy Ever Used Question


name: Was another Form of Birth Control Ever Used Question


name: Have Oral Contraceptives Ever Been Taken Question


name: Date and Method of Initial Pathologic Diagnosis


name: Date of Tumor Progression After Initial Treatment


name: Date of Tumor Reoccurrence After Initial Treatment


name: Did the Individual have Multiple Known Primary Tumors at Initial Melanoma Diagnosis Question


name: What is the First Course Treatment Completion Measure of Success of Outcome Question


name: Initial Pathologic Diagnosis Method Question


name: Did a New Event Occur After Initial Treatment Question


name: Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Loco-Regional


name: Number of Days from Date of Initial Pathologic Diagnosis to Date of Additional Surgery for New Tumor Event Metastasis


name: Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Progression after Initial Treatment


name: Number of Days from Date of Initial Pathologic Diagnosis to Date of Tumor Reoccurrence After Initial Treatment


name: Number of Discontiguous Lesions (New Tumor Event)


name: Number of Known Primaries at the Time of Initial Melanoma Diagnosis


name: Number of Other Lymph Nodes Positive for Tumor by H&E


name: Number of Other Lymph Nodes Positive for Tumor by IHC staining only


name: Number of Para-aortic Lymph Nodes Examined


name: Number of Para-aortic Lymph Nodes Positive for Tumor by H&E


name: Number of Para-aortic Lymph Nodes Positive for Tumor by IHC Staining Only


name: Number of Pelvic Lymph Nodes Positive for Tumor by H&E


name: Number of Pelvic Lymph Nodes Positive for Tumor by IHC staining only


name: Scattered Neuroendocrine Cells by Immunohistochemistry Present


name: Preoperative Karnofsky Performance Status Question


name: Preoperative ECOG - Performance Status Question


name: Were Immunophenotype and Cytochemistry Analyses Performed on Bone Marrow Aspirate Question


name: Dense Eosinophilic Basement Membrane Deposit


name: Blasts 10-20 Percent of Bone Marrow Nucleated Cells


name: Number of Primary Tumors in this Location


name: Mitotic Rate Greater than or Equal to One per Square Millimeter


name: Was Adjuvant Post-operative Radiation Therapy Administered Question


name: Was Adjuvant Post-Operative Chemotherapy Administered Question


name: Was Adjuvant Post-Operative Hormone Therapy Administered Question


name: Was Adjuvant Post-Operative Immunological Therapy Administered Question


name: Was Adjuvant Post-Operative Pharmaceutical Therapy Administered Question


name: Was Adjuvant Post-Operative Targeted Molecular Therapy Administered Question


name: Brimonidine Tartrate Nanoemulsion OCU-300


name: What is the Other Performance Status Scale: Timing Question


name: Performance Status Scale: Timing Question


name: Did the Physician Diagnose Diabetes Question


name: Is there a History of Colorectal Cancer Question


name: What is the Follow-Up Form Completion Outcome Measure of Success Question


name: Specify Other Performance Status Scale: Timing Question


name: Progression of Disease at Recurrence Question


name: No Evidence of Disease at Follow-Up Question


name: What is the Procedure Type for New Tumor Event Question


name: Other Procedure Type for New Tumor Event Question


name: What is the Status of the Residual Tumor After Surgery for New Tumor Event Question


name: Was Additional Treatment Administered for New Tumor Event Question


name: Were Immunophenotype and Cytochemistry Analyses Performed on Peripheral Blood Samples Question


name: Bone Marrow Aspirate Immunophenotype & Cytochemistry Question


name: Peripheral Blood Immunophenotype & Cytochemistry Question


name: Well-Differentiated or De-Differentiated New Tumor Question


name: Diagnostic Evidence of Recurrence/Relapse Question


name: Biopsy with Histologic Confirmation Question


name: Related to Head and Neck Cancer Question


name: Related to Acute Myeloid Leukemia Question


name: Type of New Melanoma Related Tumor Event Question


name: Did the Individual use Smokeless Tobacco Use at Diagnosis Question


name: Regular Smokeless Tobacco Use for Six Weeks or More Question


name: Average Daily Use Smokeless Tobacco after Use for Six Weeks Question


name: Age When Quit using Smokeless Tobacco after Regular Use Question


name: What is the Definitive Therapy Method Question


name: Was Evidence of Disease Present after Completion of Therapy


name: Was Tumor Progression Present After Initial Treatment Question


name: Was Tumor Reoccurrence Present After Initial Treatment Question


name: Greater than or Equal to 50% Myometrial Invasion


name: Were Local Anesthesia Agents Administered Question


name: Were Routine Cytogenetics Completed Question


name: Alcohol-free Hypoallergenic Barrier Film Solution


name: No Pathologic Evidence of Distant Metastasis Question


name: Premenopausal Greater than 6 months since LMP and no Prior Bilateral Oophorectomy and Not on Estrogen Replacement Question


name: Perimenopausal 6 to 12 Months Since LMP Question


name: Postmenopausal with no Prior Oophorectomy Status Question


name: Melanoma Related Only Event Occurred after Initial Treatment


name: Non-Melanoma Related Only Event Occurred after Initial Treatment


name: Primary Site of New Non-Melanoma Tumor Event Question


name: Histological Type of New Non-Melanoma Tumor Event Question


name: Site of New Distant Metastasis Tumor Event Question


name: Specify Molecular Abnormalities in Study


name: Days to Absolute Neutrophil Count Greater than 1000 per Microliter


name: Days to Platelet Count Greater than 100,000 per Microliter


name: del(10q23)/PTEN Gene Locus Deletion Analysis


name: del(10q23)/PTEN Gene Locus Deletion Analysis Method


name: EGFR Amplification Analysis Testing Method


name: Percent Blasts in Peripheral Blood at Diagnosis


name: Classified by World Health Organization Only Question


name: Complete Blood Count from Clinical Peripheral Blood (Within 24 Hours of Banking) Question


name: Specify Other ERBB2 Non-Exon 20 Mutation


name: MGMT Promoter Methylation Testing Method


name: PSA Level Twenty to One Hundred Fifty or Greater


name: PSA Level Greater than One Hundred Fifty


name: Is Another BRAF Mutation Present Question


name: Is Another Non-Exon 20 ERBB2 Mutation Present Question


name: Is Another KIT Mutation Present Question


name: Is Another NRAS Mutation Present Question


name: Specify Molecular Abnormality Analysis Method


name: SDH Complex Mutation Analysis Testing Method


name: Did Caregiving Responsibilities Make it Difficult to Work the Required Number of Job Hours Question


name: Did Caregiving Responsibilities Make it Difficult to Get Going Easily at Beginning of Workday Question


name: Did Caregiving Responsibilities Make it Difficult to Start Job on Arrival at Work Question


name: Did Caregiving Responsibilities Make it Difficult to do Work Without Stopping For Breaks or Rests Question


name: Did Caregiving Responsibilities Make it Difficult to Stick to Job Routine or Schedule Question


name: Have Difficulty with Sitting, Standing, or Staying in One Position Longer than 15 Minutes While Working Due to Caregiving Responsibilities Question


name: Have Difficulty Repeating Same Motions Repeatedly While Working Due to Caregiving Responsibilities Question


name: Did Caregiving Responsibilities Make it Difficult to Keep Mind on Work Question


name: Did Caregiving Responsibilities Make it Difficult to Do Work Carefully Question


name: Did Caregiving Responsibilities Make it Difficult to Think Clearly When Working Question


name: Did Caregiving Responsibilities Make it Difficult to Concentrate on Work Question


name: Did Caregiving Responsibilities Make it Difficult to Work Without Losing Train of Thought Question


name: Did Caregiving Responsibilities Make it Difficult to Easily Read or Use Eyes When Working Question


name: Did Caregiving Responsibilities Make it Difficult to Speak With People In-Person, in Meetings, or Phone When Working Question


name: Did Caregiving Responsibilities Make it Difficult to Control Temper Around People When Working Question


name: Did Caregiving Responsibilities Make it Difficult to Help Other People to Get Work Done Question


name: Proliferation of Squamous Nests with Little Stromal Reaction


name: Did Caregiving Responsibilities Make it Difficult to Listen Well to New Information Given at Work Question


name: Did Caregiving Responsibilities Make it Difficult to Control Feelings of Sadness or Grief When Working Question


name: Did Caregiving Responsibilities Make it Difficult to Handle Workload Question


name: Did Caregiving Responsibilities Make it Difficult to Work Fast Enough Question


name: Did Caregiving Responsibilities Make it Difficult to Finish Work on Time Question


name: Did Caregiving Responsibilities Make it Difficult to Do Work Without Making Mistakes Question


name: Did Caregiving Responsibilities Make it Difficult to Feel You've Done What You're Capable of Doing Question


name: Have Difficulty Doing Usual Household Chore or Activity Because of Caregiving Responsibilities Question


name: Someone There for Suggestions About How to Deal with Personal Problem Question


name: Someone There to Love and Make You Feel Wanted Question


name: Someone There to Get Together for Relaxation Question


name: Someone There to Help With Daily Chores if Sick Question


name: Someone There to Perform Caregiving Responsibilities When You Cannot Question


name: Someone There for Questions or Concerns About Caregiving Question


name: Being Able to Provide Assistance as Caregiver is Emotionally Rewarding for Me Question


name: Being Able to Provide Assistance as Caregiver is Spiritually Rewarding for Me Question


name: Being Able to Provide Assistance as Caregiver Helps Me Feel in Control of Situation Question


name: Being Able to Provide Assistance as Caregiver is Important to Me Question


name: Being Able to Provide Assistance as Caregiver is My Duty as Responsible Adult Question


name: Currently Paying Someone to Assist with Caregiving Question


name: Plan to Take Leave of Absence From Work Over Next Year Because of Caregiving Question


name: CO2 Level at Organ Excision Time Question


name: Cytogenetic Abnormality Positive by FISH


name: Small, Stellate, or Spindled Cells Present


name: Homologous Recombination Repair Proficient


name: Was Interferon Gamma Treatment Administered Prior to Specimen Resection Question


name: Was Interferon Gamma Treatment Administered 90 Days Prior to Specimen Resection Question


name: Method of Left Lymph Node Dissection Question


name: Method of Right Lymph Node Dissection Question


name: Other Notable Events During Surgery Question


name: Description of Epochs of O2 Desaturation Less than 92% Greater than 5 Minutes Prior to Organ Excision Question


name: Melanoma Involvement of Regional Cutaneous or Subcutaneous Tissue


name: Intraoperative Blood Product Administration Question


name: Were Other Medications Administered During Surgery Question


name: Antibiotics Administered During Surgery Question


name: Were Steroids Administered During Surgery Question


name: Was Insulin Administered During Surgery Question


name: Other Medications Administered During Surgery Prior to Tumor Tissue Removal Question


name: Surgery Information Indicate If any of the Following Medications were Administered During Surgery


name: Was Inhalation Anesthesia Administered Question


name: Specify Other Muscle Relaxants Administered Question


name: Were IV Muscle Relaxants Administered Question


name: Specify Other Narcotics or Opiates Administered Question


name: Was Regional Anesthesia Administered Question


name: Were Other Preoperative IV Medications Administered Question


name: Were Preoperative IV Antacids Administered Question


name: Were Preoperative IV Antiemetics Administered Question


name: Were Preoperative IV Opiates Administered Question


name: Specify Other Preoperative IV Sedation Administered Question


name: Was Preoperative IV Sedation Administered Question


name: Highest Grade Pancreatic Intraepithelial Neoplasia Question


name: Which Pulmonary Function Tests Were Performed Question


name: Pathologic Findings in Non-Neoplastic Kidney Question


name: Prognostic Features Used for Tumor Prognosis Question


name: Renal Vein or Vena Cava Thrombosis or Other Coagulopathies Question


name: HPV Status by in situ Hybridization Question


name: CPTAC Acute Myeloid Leukemia Baseline Form


name: Prepare and Give Medicines, Fluids, Nutrition Intravenously Question


name: Prepare and Give Medicine as Shot in Muscle or Under Skin Question


name: Prepare and Give Medications by Mouth Question


name: Prepare and Give Catheter Flushes Question


name: Change Dressing on Your Child's Catheter and Change Catheter Cap Question


name: Manage Child's Side Effects of Cancer or its Treatment Question


name: Keep Your Child Comfortable and Without Pain Question


name: Manage Other Childhood Illnesses for Your Child with Cancer Question


name: Manage Unexpected Events Related to Your Child's Illness Question


name: Additional Household Tasks Related to Your Child's Illness Question


name: Coordinate, Arrange, and Manage Child's Medical Services Question


name: Travel to and From Hospital for Medical Care Question


name: How Much Time Spent at Hospital for Appointments Question


name: How Much Effort or Difficulty for Time Spent at Hospital for Appointments Question


name: Provide Emotional Support for Your Child with Cancer Question


name: Provide Emotional Support for Other Children in the Family Question


name: Provide Emotional Support for Extended Family Question


name: Provide Support for Spouse or Partner Question


name: Meet Your Own Emotional Support Needs Question


name: Comfort Your Child Through Pain of Cancer and its Treatment Question


name: Take Care of Discipline and/or Behavior Problems of Child with Cancer Question


name: Take Care of Finances, Bills, and Forms Related to Child's Illness Question


name: Plan Activities for Your Child with Cancer Around Treatment and Illness Question


name: Plan Activities for Your Family Around Treatment and Illness Question


name: Get Child Care or Babysitting Help for Your Ill Child Question


name: Get Child Care or Babysitting for Siblings of Ill Child Question


name: Communicate Information About Cancer to Schools, Day Care, Babysitters, Extended Family, and Friends Question


name: Watch for and Report Your Child's Physical Symptoms and Medical Condition to Medical Team Question


name: Get Information on Your Child's Illness and Treatment Question


name: Anything Else You Wish to Tell About Taking Care of Your Child with Cancer Question


name: CPTAC Uterine Corpus Endometrial Carcinoma Baseline Form


name: CPTAC Lung Squamous Cell Carcinoma and Lung Adenocarcinoma Baseline Form


name: CPTAC Clear Cell Renal Cell Carcinoma Baseline Form


name: CPTAC Head and Neck Squamous Cell Carcinoma Baseline Form


name: CPTAC Glioblastoma Multiforme Baseline Form


name: Regimen Used to Treat Malignant Thymus Neoplasm


name: Regimen Used to Treat Malignant Anal Neoplasm


name: Regimen Used to Treat Chronic Myeloid Leukemia


name: Regimen Used to Treat Merkel Cell Carcinoma


name: Regimen Used to Treat Myelodysplastic Syndromes


name: Regimen Used to Treat Hepatobiliary Cancer


name: Regimen Used to Treat Plasma Cell Neoplasm


name: Regimen Used to Treat Primary Amyloidosis


name: Regimen Used to Treat Malignant Soft Tissue Neoplasm


name: Carcinoma Exhibiting Undifferentiated or Dedifferentiated Features


name: Wheelchair Independent, Greater Than 50 Yards


name: Walks with Help of One Person, Greater Than 50 Yards


name: Additional Anesthesia Agents Used Question


name: Were IV Narcotic/Opiate Agents Administered Question


name: Radium Ra 224-labeled Calcium Carbonate Microparticles


name: Was EGFR Amplification Assessed Question


name: Validated Hemophilia Regimen Treatment Adherence Scale - On-Demand


name: Validated Hemophilia Regimen Treatment Adherence Scale - Prophylaxis


name: Indeterminate Macroscopic Satellite Nodule Question


name: Other Site of New Distant Metastasis Tumor Event Question


name: Specify Site of Other New Tumor Event Question


name: Other Site of New Primary Melanoma Question


name: Was the Individual Exposed to Second-Hand Smoke Question


name: Chemical/Occupational Exposure Type Unknown


name: Specify Other Inhalation Anesthesia Agents Question


name: Specify Other Preoperative IV Anesthesia Administered Question


name: Preoperative IV Sedation was Not Administered


name: Preoperative IV Sedation was Administered


name: Preoperative IV Opiates were Administered


name: Other Preoperative IV Medications were Administered


name: Preoperative IV Antiemetics were Administered


name: Preoperative IV Antacids were Administered


name: Preoperative IV Antacids were not Administered


name: Preoperative IV Antiemetics were not Administered


name: Other Preoperative IV Medications were not Administered


name: Preoperative IV Opiates were not Administered


name: Local Anesthesia Agents were not Administered


name: Local Anesthesia Agents were Administered


name: Regional Anesthesia was not Administered


name: Was Molecular Analysis Performed Question


name: Response Evaluation Criteria In Lymphoma 2017


name: Indeterminate or Unknown Menopause Status Question


name: Were Additional Molecular Studies Performed Question


name: Was 10q23/PTEN Locus Deletion Analysis Performed Question


name: Was 1p/19q Deletion Analysis Performed Question


name: Was ATRX Mutation Analysis Performed Question


name: Was BRAF Mutation Analysis Performed Question


name: Was ERBB2 Mutation Analysis Performed Question


name: Was IDH Family Mutation Analysis Performed Question


name: Was Immunohistochemical Testing Performed Question


name: Was Additional Immunohistochemical Testing Performed Question


name: Was Additional Mutation Analysis Performed Question


name: Was KIT Mutation Analysis Performed Question


name: Was KRAS Mutation Analysis Performed Question


name: Was Lymph Node Dissection Performed Question


name: Was MET Mutation Analysis Performed Question


name: Was MGMT Promoter Methylation Testing Performed Question


name: Was NF1 Mutation Analysis Performed Question


name: Was NRAS Mutation Analysis Performed Question


name: Was PTEN Mutation Analysis Performed Question


name: Was SDH Complex Mutation Analysis Performed Question


name: Was TP53 Mutation Analysis Performed Question


name: Was Fluorescence In Situ Hybridization Performed Question


name: Regimen Used to Treat or Prevent Graft Rejection


name: Autologous Stem Cell Transplant Recipient


name: Allogeneic Stem Cell Transplant Recipient


name: ECOG Performance Status not Evaluated, not Provided or Available Question


name: Unknown ECOG Performance Status Question


name: modified Severity Weighted Assessment Tool


name: First Visit Year with All Necessary Components to Determine


name: First Visit with All Necessary Components to Determine


name: Specify Site If Distant Metastasis Submitted Question


name: Specify New Tumor Metastasis Site Question


name: How Many Places Lived with Child Question


name: Struggle with Rent or Mortgage Due to Financial Difficulties Question


name: Live with Others Due to Financial Difficulties Question


name: Lack of Reliable Transportation Keeps from Appointments, Meetings, Work, or Daily Living Question


name: Utility Company Threatened to Shut Off Services for not Paying Bills Question


name: Utility Company Shut Off Services for not Paying Bills Question


name: Days Home Not Heated or Cooled Because Bills Not Paid Question


name: Used Cooking Stove to Heat Home Because Bills Not Paid Question


name: Telephone Service Disconnected Due to Bill Not Paid Question


name: Worried Food Would Run Out Before Get Money to Buy More Question


name: Food Bought Didn't Last and Didn't Have Money to Get More Question


name: If Lose Current Income Sources and Live Off Savings, How Long Could Continue to Live at Current Address and Standard of Living Question


name: Family Received Food from Food Pantry or Soup Kitchen Question


name: Family Received Energy Assistance Question


name: Family Received Disability Benefits Question


name: Family Received Low-Income or Subsidized Housing Question


name: Family Received Free or Subsidized School Lunch Question


name: Family Received Employment Insurance Question


name: Family Received Canada Child Benefit Question


name: Family Received Disability Tax Credit Question


name: Shelter or Transitional Living Situation


name: Specify Number of Lymph Nodes Positive for Tumor by IHC Staining Only Question


name: Specify Number of Lymph Nodes Positive for Tumor by H&E Question


name: Greater than or equal to Four Pregnancies


name: Testosterone Greater than or Equal to 150 ng/dL


name: Fanconi Anemia Complementation Group Gene Mutation Negative


name: International Myeloma Working Group Minimal Residual Disease Criteria


name: International Myeloma Working Group Standard Response Criteria


name: Outcome Measure of Success at Completion of Initial Treatment Course Not Applicable Question


name: Outcome Measure of Success at Completion of Initial Treatment Unknown Question


name: Performance Status Scale Timing Not Applicable


name: Can't Hear Yourself Think at Home Question


name: Have a Regular Morning Routine in Our Home Question


name: Able to Adapt When Changes Occur Question


name: Can Deal with Whatever Comes my Way Question


name: Try to See Humorous Side of Things When Faced with Problems Question


name: Having to Cope with Stress can Make me Stronger Question


name: Tend to Bounce Back After Illness, Injury, or Other Hardships Question


name: Can Achieve my Goals, Even if There are Obstacles Question


name: Not Easily Discouraged by Failure Question


name: Think of Myself as a Strong Person When Dealing with Life's Challenges and Difficulties Question


name: Able to Handle Unpleasant or Painful Feelings Question


name: Treated with Less Courtesy or Respect than Other People Question


name: Receive Poorer Service Than Other People at Restaurant or Stores Question


name: People Act as if They Think You are Not Smart Question


name: People Act as if They are Afraid of You Question


name: Specify Other Non-Neoplastic Finding Question


name: Regimen Used to Treat Malignant Bone Marrow Neoplasm


name: Retrograde Selective Washing of Upper Tract


name: Body Mass Index Greater than or Equal to 30


name: Regimen Used to Treat Malignant Intestinal Neoplasm


name: Was a New Tumor Event Present After Initial Treatment Question


name: Regimen Used to Treat Malignant Fallopian Tube Neoplasm


name: Regimen Used to Treat Malignant Peritoneal Neoplasm


name: Lymphedema Symptom Intensity and Distress Survey - Arm


name: Regimen Used to Treat Malignant Germ Cell Tumor


name: Regimen Used to Treat Malignant Reproductive Endocrine Neoplasm


name: Have Difficulty Moving Arm Side to Side Question


name: Have Difficulty Raising Arm Above Head Question


name: Have Lack of Confidence in Self Question


name: Have Lack of Confidence in Insurance Provider Question


name: Have Concerns About How You Look Question


name: Feel Misunderstood by Spouse or Significant Other Question


name: Feel Frustration with Insurance Company Question


name: Have Loss of Confidence in Body Question


name: Partner Has Lack of Interest in Sex Question


name: Have Inability to Complete Hobbies or Leisure Activities Question


name: Consistently Decreased Social Activities Question


name: Have Decrease in Sexual Activity Question


name: Symptoms Intensity and Distress Likert Scale


name: Fluorouracil Continuous Infusion Regimen


name: Methotrexate Intra-Cerebrospinal Fluid Regimen


name: Intralesional Interferon Alfa-2b Regimen


name: Talimogene Laherparepvec Intralesional Regimen


name: Rituximab and Hyaluronidase Human Regimen


name: Unknown Supratentorial Localization Question


name: Therapeutic Ionizing Radiation to Head History Present


name: Therapeutic Ionizing Radiation to Head History Absent


name: Therapeutic Ionizing Radiation to Head History Unknown


name: First Degree Family History Cancer Positive


name: First Degree Family History Cancer Negative


name: First Degree Family History Cancer Unknown


name: First Degree Family History of Primary Brain Tumor Positive


name: First Degree Family History of Primary Brain Tumor Negative


name: First Degree Family History of Primary Brain Tumor Unknown


name: Was an IDH Family Mutation Identified Question


name: First Presenting Symptom Related to Disease Unknown


name: Was an ATRX Mutation Identified Question


name: Was an EGFR Amplification Identified Question


name: Family History of Stomach Cancer Present


name: First Degree Family History Thyroid Cancer Negative


name: First Degree Family History Thyroid Cancer Positive


name: First Degree Family History Thyroid Cancer Unknown


name: Needed Medical Care or Prescription Medicine but Unable to Afford it Question


name: Who Needed Medical Care but Family Unable to Afford it Question


name: Who Needed Prescription Medicine but Family Unable to Afford it Question


name: First Course Treatment Completion Measure of Success of Outcome Not Applicable


name: Patient was Postmenopausal with no Prior Oophorectomy


name: Patient was not Postmenopausal with no Prior Oophorectomy


name: Currently Using Menopausal Hormone Therapy


name: Formerly Used Menopausal Hormone Therapy


name: Unknown Use of Menopausal Hormone Therapy


name: Another Form of Birth Control was not Used


name: Unknown if Another form of Birth Control was Used


name: Specify Another Form of Birth Control that was Used Question


name: Adjuvant Post-operative Radiation Therapy Was Administered


name: Adjuvant Post-operative Radiation Therapy Was Not Administered


name: Adjuvant Post-operative Radiation Therapy Administration Unknown


name: Adjuvant Post-operative Pharmaceutical Therapy Was Administered


name: Adjuvant Post-operative Pharmaceutical Therapy Was Not Administered


name: Adjuvant Post-operative Pharmaceutical Therapy Administration Unknown


name: Adjuvant Post-operative Immunological Therapy Was Administered


name: Adjuvant Post-operative Immunological Therapy Was Not Administered


name: Adjuvant Post-operative Immunological Therapy Administration Unknown


name: Does the Individual have Hypertension Question


name: Follow-Up Form Outcome Measure of Success Not Applicable


name: New Tumor Event After Initial Treatment Absent


name: New Tumor Event After Initial Treatment Unknown


name: Additional Surgery for New Tumor Event Present


name: Additional Surgery for New Tumor Event Absent


name: Additional Surgery for New Tumor Event Unknown


name: Not Known if Additional Testing Was Performed


name: 10q23/PTEN Locus Deletion Analysis Was Not Performed


name: 10q23/PTEN Locus Deletion Analysis Was Performed


name: Unknown Procedure Type for New Tumor Event


name: 1p/19q Deletion Analysis Was Not Performed


name: Additional Immunohistochemistry Was Not Performed


name: Additional Immunohistochemistry Was Performed


name: Additional Molecular Studies Were Not Performed


name: Additional Molecular Studies Were Performed


name: ALK Rearrangement Analysis Was Not Performed


name: ALK Rearrangement Analysis Was Performed


name: ATRX Mutation Analysis Was Not Performed


name: Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Not Performed


name: Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed


name: Bone Marrow Transplantation Not Performed


name: Bone Marrow Transplantation Status Unknown


name: BRAF Mutation Analysis Was Not Performed


name: BRAF Rearrangement Analysis Was Not Performed


name: EGFR Amplification Analysis Was Not Performed


name: EGFR Amplification Analysis Was Performed


name: EGFR Mutation Analysis Was Not Performed


name: ERBB2 Mutation Analysis Was Not Performed


name: Adjuvant Post-operative Chemotherapy Was Administered


name: Adjuvant Post-operative Chemotherapy Was Not Administered


name: Adjuvant Post-operative Chemotherapy Administration Unknown


name: Adjuvant Post-operative Hormone Therapy Was Administered


name: Adjuvant Post-operative Hormone Therapy Was Not Administered


name: Adjuvant Post-operative Hormone Therapy Administration Unknown


name: IDH Family Mutation Analysis Was Not Performed


name: IDH Family Mutation Analysis Was Performed


name: Not Known if Mutation Analysis Was Performed


name: Not Known if Additional Immunohistochemistry Was Performed


name: Not Known if Additional Molecular Studies Were Performed


name: Not Known if Immunohistochemistry Was Performed


name: Adjuvant Post-operative Targeted Molecular Therapy Was Administered


name: Adjuvant Post-operative Targeted Molecular Therapy Was Not Administered


name: Adjuvant Post-operative Targeted Molecular Therapy Administration Unknown


name: First Course Treatment Completion Measure of Success of Outcome Unknown


name: KRAS Mutation Analysis Was Not Performed


name: Follow-Up Form Completion Outcome Measure of Success Unknown


name: Follow-Up Form Completion Outcome Measure of Success Not Applicable


name: MGMT Promoter Methylation Testing Was Not Performed


name: MGMT Promoter Methylation Testing Was Performed


name: MLH1 Gene Promoter Hypermethylation Status


name: Not Known if 10q23/PTEN Locus Deletion Analysis Was Performed


name: Not Known if 1p/19q Deletion Analysis Was Performed


name: Not Known if ALK Rearrangement Analysis Was Performed


name: Not Known if ATRX Mutation Analysis Was Performed


name: Not Known if Bone Marrow Aspirate Immunophenotyping and Cytochemistry Were Performed


name: Not Known if BRAF Mutation Analysis Was Performed


name: Not Known if BRAF Rearrangement Analysis Was Performed


name: Was Additional Surgery for New Loco-Regional Tumor Event Performed Question


name: Was Additional Surgery for New Metastatic Tumor Event Performed Question


name: Date of Additional Surgery for New Tumor Event: Loco-Regional Question


name: Date of Additional Surgery for New Tumor Event: Metastatic Question


name: Additional Surgery for New Loco-Regional Tumor Event Was Performed


name: Additional Surgery for New Loco-Regional Tumor Event Was Not Performed


name: Additional Surgery for New Loco-Regional Tumor Event Unknown


name: Additional Surgery for New Metastatic Tumor Event Unknown


name: Additional Surgery for New Metastatic Tumor Event Was Not Performed


name: Additional Surgery for New Metastatic Tumor Event Was Performed


name: Not Known if EGFR Amplification Analysis Was Performed


name: Not Known if EGFR Mutation Analysis Was Performed


name: Not Known if ERBB2 Mutation Analysis Was Performed


name: Not Known if IDH Family Mutation Analysis Was Performed


name: Not Known if KIT Mutation Analysis Was Performed


name: Not Known if KRAS Mutation Analysis Was Performed


name: Not Known if Lymph Node Dissection Was Performed


name: Not Known if MET Mutation Analysis Was Performed


name: Not Known if MGMT Promoter Methylation Testing Was Performed


name: Not Known if NF1 Mutation Analysis Was Performed


name: Not Known if NRAS Mutation Analysis Was Performed


name: Not Known if PDGFRA Mutation Analysis Was Performed


name: Not Known if Peripheral Blood Immunophenotyping and Cytochemistry Were Performed


name: Not Known if PTEN Mutation Analysis Was Performed


name: Not Known if RET Rearrangement Analysis Was Performed


name: Use of Smokeless Tobacco at Time of Diagnosis Positive


name: Not Known if ROS1 Rearrangement Analysis Was Performed


name: Use of Smokeless Tobacco at Time of Diagnosis Negative


name: Use of Smokeless Tobacco at Time of Diagnosis Unknown


name: Regular Smokeless Tobacco Use for Six Weeks or More Positive


name: Regular Smokeless Tobacco Use for Six Weeks or More Negative


name: Regular Smokeless Tobacco Use for Six Weeks or More Unknown


name: Average Daily Use Smokeless Tobacco after Use for Six Weeks Unknown


name: Never Quit using Smokeless Tobacco after Regular Use Question


name: Not Known if SDH Complex Mutation Analysis Was Performed


name: Not Known if TP53 Mutation Analysis Was Performed


name: NRAS Mutation Analysis Was Not Performed


name: PDGFRA Mutation Analysis Was Not Performed


name: Peripheral Blood Immunophenotyping and Cytochemistry Were Not Performed


name: Peripheral Blood Immunophenotyping and Cytochemistry Were Performed


name: PTEN Mutation Analysis Was Not Performed


name: Intravesical Bacillus Calmette-Guerin Therapy Failure


name: RET Rearrangement Analysis Was Not Performed


name: RET Rearrangement Analysis Was Performed


name: ROS1 Rearrangement Analysis Was Not Performed


name: ROS1 Rearrangement Analysis Was Performed


name: SDH Complex Mutation Analysis Was Not Performed


name: SDH Complex Mutation Analysis Was Performed


name: Antithymocyte Globulin Rabbit/Tacrolimus Regimen


name: Horse Antithymocyte Globulin/Tacrolimus Regimen


name: Rabbit Anti-thymocyte Globulin/Prednisone/Tacrolimus Regimen


name: Equine Anti-thymocyte Globulin/Prednisone/Tacrolimus Regimen


name: Dose-adjusted R-EPOCH Plus High-dose Methotrexate Regimen


name: R-CODOX-M Alternating with R-IVAC Regimen


name: TP53 Mutation Analysis Was Not Performed


name: Was ALK Rearrangement Analysis Performed Question


name: Was BRAF Rearrangement Analysis Performed Question


name: Was PDGFRA Mutation Analysis Performed Question


name: Was RET Rearrangement Analysis Performed Question


name: Was ROS1 Rearrangement Analysis Performed Question


name: Was EGFR Mutation Analysis Performed Question


name: Fluorescence In Situ Hybridization Was Performed


name: Fluorescence In Situ Hybridization Was Not Performed


name: Not Known if Fluorescence In Situ Hybridization Was Performed


name: Unknown Age When Started using Smokeless Tobacco after Regular Use Question


name: Evidence of Disease Present after Completion of Therapy


name: Evidence of Disease Absent after Completion of Therapy


name: Evidence of Disease Unknown after Completion of Therapy


name: Non-Concurrent Chemotherapy was Curative Therapy


name: Concurrent Chemotherapy was Curative Therapy


name: Tumor Reoccurrence Present After Initial Treatment


name: Tumor Reoccurrence Absent After Initial Treatment


name: Tumor Reoccurrence Unknown After Initial Treatment


name: Tissue Expander-Implant Breast Reconstruction


name: Was Radiation Administered as an Additional Treatment for a New Tumor Event Question


name: Was Chemotherapy Administered as an Additional Treatment for a New Tumor Event Question


name: Was Immunotherapy Administered as an Additional Treatment for a New Tumor Event Question


name: Was Hormone Therapy Administered as an Additional Treatment for a New Tumor Event Question


name: Was Targeted Molecular Therapy Administered as an Additional Treatment for a New Tumor Event Question


name: Radiation Was Administered as an Additional Treatment for a New Tumor Event


name: Radiation Was Not Administered as an Additional Treatment for a New Tumor Event


name: Unknown if Radiation Was Administered as an Additional Treatment for a New Tumor Event


name: Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event


name: Chemotherapy Was Not Administered as an Additional Treatment for a New Tumor Event


name: Unknown if Chemotherapy Was Administered as an Additional Treatment for a New Tumor Event


name: Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event


name: Immunotherapy Was Not Administered as an Additional Treatment for a New Tumor Event


name: Unknown if Immunotherapy Was Administered as an Additional Treatment for a New Tumor Event


name: Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event


name: Hormone Therapy Was Not Administered as an Additional Treatment for a New Tumor Event


name: Unknown if Hormone Therapy Was Administered as an Additional Treatment for a New Tumor Event


name: Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event


name: Targeted Molecular Therapy Was Not Administered as an Additional Treatment for a New Tumor Event


name: Unknown if Targeted Molecular Therapy Was Administered as an Additional Treatment for a New Tumor Event


name: Melanoma and Non-Melanoma Related Event Occurred after Initial Treatment


name: Was Additional Pharmaceutical Treatment for New Tumor Event Administered Question


name: Number of Days from Date of Collection to Date of Last Contact


name: Chemical/Occupational Exposure History Unknown


name: Family History of Stomach Cancer Unknown


name: Additional Pharmacotherapy for New Tumor Event Absent


name: Additional Pharmacotherapy for New Tumor Event Received


name: Additional Pharmacotherapy for New Tumor Event Unknown


name: Tumor Invasion of the Prostatic Ducts and Acini


name: Indeterminate Extranodal Tumor Extension


name: Multiple Known Primary Tumors Present at Initial Melanoma Diagnosis


name: Multiple Known Primary Tumors Absent at Initial Melanoma Diagnosis


name: Multiple Known Primary Tumors Unknown at Initial Melanoma Diagnosis


name: Is Paraneoplastic Syndrome Present Question


name: Paraneoplastic Syndrome Status is Unknown


name: Tumor Progression Present After Initial Treatment


name: Tumor Progression Absent After Initial Treatment


name: Tumor Progression Unknown After Initial Treatment


name: Subsequent Known Primary Melanoma(s) Found During the Follow-Up


name: Subsequent Known Primary Melanoma(s) Not Found During the Follow-Up


name: Additional Surgery for New Metastatic Tumor Event Not Evaluated


name: Was Bone Marrow Transplantation Performed Question


name: Was Radiation Therapy Administered Question


name: Was Pharmacotherapy Administered Question


name: Unknown if Routine Cytogenetics were Completed


name: Other Cytogenetic Analysis Abnormality Type


name: Specify if Other Cytogenetic Analysis Abnormality Type


name: Were Molecular Abnormalities Detected Question


name: Discrete Set Telecommunication URL Data Type


name: Regimen Used to Treat Non-neoplastic Hematologic Disorders


name: Histologic Grade for Other Carcinomas Question


name: Peritoneal Fluid is Negative for Malignancy


name: Peritoneal Fluid Positive for Malignancy


name: Macroscopic Satellite Nodule Not Identified Question


name: Are Tumor Infiltrating Lymphocytes Present Question


name: Is Extranodal Tumor Involvement Present Question


name: Interferon Gamma Treatment was Administered Prior to Specimen Resection


name: Interferon Gamma Treatment was not Administered Prior to Specimen Resection


name: Unknown if Interferon Gamma Treatment was Administered Prior to Specimen Resection


name: Interferon Gamma Treatment was Administered 90 Days Prior to Specimen Resection


name: Interferon Gamma Treatment was not Administered 90 Days Prior to Specimen Resection


name: Interferon Gamma Treatment Administration 90 Days Prior to Specimen Resection Unknown


name: Are Sarcomatoid Features Present Question


name: Elevated Type I Collagen Cross-Linked N-Telopeptide


name: Test of Word Reading Efficiency, Second Edition


name: Oral Mechanism/Cranial Nerve Examination for Young Children


name: Head and Neck Survivorship Tool: Assessment and Recommendations


name: Computed Spanish/Hispanic Ethnicity Code


name: CDISC Protocol Study Population Attribute Terminology


name: CDISC SDTM Laboratory Analytical Method Calculation Formula Terminology


name: CDISC SDTM Model Version ResponseTerminology


name: CDISC SDTM Implementation Guide Version Response Terminology


name: CDISC Therapeutic Area User Guide Response Terminology


name: CDISC SDTM FDA Technical Specification Response Terminology


name: CDISC SEND Body Irradiation Model Response Terminology


name: CDISC SEND Rad/Nuc Targeted Injury Model Response Terminology


name: CDISC SEND Chemical Challenge Agent Name Response Terminology


name: CDISC SEND Genus and Species Response Terminology


name: Beta-lactamase Positive Bacteria Measurement


name: Beta-lactamase Negative Bacteria Measurement


name: Blasts 15 Percent or Less of Bone Marrow Nucleated Cells


name: Non-Cogstate Baseline and Follow-up Measures


name: Transglottic Extension of Laryngeal Tumor


name: Automated Video-Assisted Smoking Treatment


name: Glottic Laryngeal Tumor with Subglottic Extension


name: Morphologic Features Resembling Salivary Gland Adenocarcinoma


name: Supraventricular Trigeminy by ECG Finding


name: Evidence of Malignant Disease Description


name: CDISC Diabetes Therapeutic Area User Guide Version 1.0 - Supplement for ADaM


name: Robot-Assisted Salvage Pelvic Lymph Node Dissection


name: Robot-assisted Salvage Pelvic Mass Resection


name: Kappa Light Chain to Lambda Light Chain Ratio Measurement


name: Cytochrome P450 2C9 Activity Measurement


name: Progressive Spermatozoa to Total Spermatozoa Ratio Measurement


name: pH Adjusted for Body Temperature Measurement


name: Thyroid Stimulating Immunoglobulin Actual to Control Ratio Measurement


name: APTT-LA Actual to Control Ratio Measurement


name: Thrombin Time Actual to Control Ratio Measurement


name: APTT-LA Screen to Confirm Percent Difference


name: dRVVT Screen to Confirm Percent Difference


name: Choriogonadotropin Adjusted for Maternal Weight Measurement


name: Neisseria gonorrhoeae, Beta-lactamase Positive Measurement


name: Neisseria gonorrhoeae, Beta-lactamase Negative Measurement


name: Multiple Inert Gas Elimination Technique


name: No Steroid Use Beyond Physiologic Replacement Dose


name: Natural Log Transformed Observed Area Under the Curve Infinity


name: Natural Log Transformed Area Under the Curve From Dosing to Last Concentration


name: CDISC SDTM Implementation Guide Version 3.1.1


name: CDISC SDTM Implementation Guide Version 3.1.2


name: CDISC SDTM Implementation Guide Version 3.1.2 Amendment 1


name: CDISC SDTM Implementation Guide Version 3.1.3


name: CDISC Chronic Hepatitis C Therapeutic Area User Guide Version 1.0


name: CDISC Diabetic Kidney Disease Therapeutic Area User Guide Version 1.0


name: CDISC Duchenne Muscular Dystrophy Therapeutic Area User Guide Version 1.0


name: CDISC Dyslipidemia Therapeutic Area User Guide Version 1.0


name: CDISC Ebola Therapeutic Area User Guide Version 1.0


name: CDISC Influenza Therapeutic Area User Guide Version 1.1


name: CDISC Influenza Therapeutic Area User Guide Version 1.0


name: CDISC Kidney Transplant Therapeutic Area User Guide Version 1.0


name: CDISC Major Depressive Disorder Therapeutic Area User Guide Version 1.0


name: CDISC Malaria Therapeutic Area User Guide Version 1.0


name: CDISC Prostate Cancer Therapeutic Area User Guide Version 1.0


name: CDISC QT Studies Therapeutic Area User Guide Version 1.0


name: CDISC Rheumatoid Arthritis Therapeutic Area User Guide Version 1.0


name: CDISC Schizophrenia Therapeutic Area User Guide Version 1.1


name: CDISC Schizophrenia Therapeutic Area User Guide Version 1.0


name: CDISC Traumatic Brain Injury Therapeutic Area User Guide Version 1.0


name: CDISC Tuberculosis Therapeutic Area User Guide Version 2.0


name: CDISC Vaccines Therapeutic Area User Guide Version 1.1


name: CDISC Virology Therapeutic Area User Guide Version 2.1


name: CDISC Virology Therapeutic Area User Guide Version 2.0


name: CDISC Alzheimer's Therapeutic Area User Guide Version 1.0


name: CDISC Alzheimer's Therapeutic Area User Guide Version 2.0


name: CDISC Asthma Therapeutic Area User Guide Version 1.0


name: CDISC Breast Cancer Therapeutic Area User Guide Version 1.0


name: CDISC Cardiovascular Studies Therapeutic Area User Guide Version 1.0


name: CDISC Colorectal Cancer Therapeutic Area User Guide Version 1.0


name: CDISC COPD Therapeutic Area User Guide Version 1.0


name: CDISC HIV Therapeutic Area User Guide Version 1.0


name: CDISC Huntington's Disease Therapeutic Area User Guide Version 1.0


name: CDISC Multiple Sclerosis Therapeutic Area User Guide Version 1.0


name: CDISC Pain Therapeutic Area User Guide Version 1.0


name: CDISC Pain Therapeutic Area User Guide Version 1.1


name: CDISC Parkinson's Disease Therapeutic Area User Guide Version 1.0


name: CDISC Polycystic Kidney Disease (PKD) Therapeutic Area User Guide Version 1.0


name: CDISC Post Traumatic Stress Disorder Therapeutic Area User Guide Version 1.0


name: US FDA HIV Technical Specifications Guidance v1.0


name: US FDA Vaccines Technical Specification Guidance v1.0


name: US FDA Clinical Endpoint BE Studies v1.0


name: US FDA Study Data Technical Conformance Guide v4.2.1


name: Expected Onset of Rad/Nuc Targeted Injury


name: Chemical Agent Certificate of Analysis Indicator


name: Chemical Agent Material Identification Code


name: Total Body Irradiation Plus Bone Marrow Transplant


name: Total Body Irradiation with Bone Marrow Not Irradiated


name: Narrowed Filtration Angle of Trabecular Meshwork


name: Experimental Organism Increased Number of Glial Cells


name: Bio-enhanced Curcumin Extract Formulation


name: Increased Fibroblast Growth Factor Pathway Activation


name: CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Name Terminology


name: CDISC Questionnaire EORTC QLQ-C15-PAL Version 1 Test Code Terminology


name: CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Name Terminology


name: CDISC Questionnaire EORTC QLQ-C30 Version 3 Test Code Terminology


name: CDISC Questionnaire T1-DDS Test Name Terminology


name: CDISC Questionnaire T1-DDS Test Code Terminology


name: CDISC Clinical Classification AVPU Test Name Terminology


name: CDISC Clinical Classification AVPU Test Code Terminology


name: CDISC Clinical Classification BPRS 1988 Version Test Name Terminology


name: CDISC Clinical Classification BPRS 1988 Version Test Code Terminology


name: CDISC Clinical Classification E-TRIP Test Name Terminology


name: CDISC Clinical Classification E-TRIP Test Code Terminology